China National Accord Medicines Corporation Ltd. (SZSE:000028) agreed to acquire Guangdong Oriental New & Special Drugs Corporation from Sinopharma Holdings for CNY 1.3 billion on January 4, 2017. Under the terms, China National Accord Medicines Corporation Ltd will issue 10.8 million shares at CNY 53.5 per share and pay CNY 576.9 million in cash. In related deals, China National Accord Medicines Corporation Ltd. agreed to sell 51% stake in three companies acquire stakes in three companies from Sinopharma Holdings. China National Accord Medicines Corporation Ltd. will issue total 55.1 million shares for the acquisitions. Ding Xuedong, Zhang Lei, Chen Chao and Sun Fang of China International Capital Corporation Limited (SEHK:3908) acted as financial advisors, Wu Xiaoliang, Zhou Yijie and Huang Ningning of Guohao Law Firm acted as legal advisors, Tang Zhenfeng, Liu Likun, Xu Shi, Tang Pina, Zhao Xia, Ying Yan Li and Li Dan of PricewaterhouseCoopers Zhong Tian LLP and Fu Chenggang, Han Yanguang, Mai Jianqing and Chen Yonghong of Vocation International Certified Public Accountant Co., Ltd. acted as accountants and Peng Jie, Hou Xiaoli and Sun Jiemin of Beijing Tianjian Xingye Assets Appraisal Co., Ltd and Jiang Shubao, Yao Yongjun and Quan Zhongguang of Beijing Zhonghua China Assets Appraisal Co., Ltd. acted as asset appraisers for China National Accord Medicines Corporation Ltd. China National Accord Medicines Corporation Ltd. (SZSE:000028) completed the acquisition of Guangdong Oriental New & Special Drugs Corporation from Sinopharma Holdings on January 4, 2018.